IC-8 Apthera IOL New Enrollment Post Approval Study

Part of paid clinical trials in Dothan, Alabama.

Sponsor
Bausch & Lomb Incorporated
Study ID
NCT06060041
Status
Recruiting

Conditions

  • Cataract
  • Posterior Capsule Opacification
  • Presbyopia

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

Key Dates

Start date
Sep 8, 2023
Status verified
Jan 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
435 participants (estimated)

Arms

  • Arm: IC-8 Apthera intraocular lens (IOL) Group
    Patients previously implanted with the IC-8 Apthera intraocular lens (IOL) and who have developed posterior capsular opacification (PCO) which requires treatment with Nd:YAG laser capsulotomy.

Primary Outcome Measure

Rate of any additional Nd:YAG laser treatments beyond the initial Nd:YAG laser treatment [ Time Frame: 24 Months post IC-8 Apthera IOL Implantation ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
Trinity Research Group, LLCDothanAlabama36301-
Feinerman Vision CenterNewport BeachCalifornia92663
OD
Argus Research CenterCape CoralFlorida33909-
Stephenson Eye AssociatesVeniceFlorida34285-
Virdi Eye Clinic and Laser Vision CenterRock IslandIllinois61201-
Price Vision GroupIndianapolisIndiana46260-
Grene Vision GroupWichitaKansas67206-
Oakland EyeBirminghamMichigan48009-
Vance Thompson Vision - OmahaOmahaNebraska68137-
Eye Associates of New JerseyDoverNew Jersey07801-
Northern New Jersey Eye InstituteSouth OrangeNew Jersey07079-
Ophthalmic Partners, PCBala-CynwydPennsylvania19004-
Berkeley Eye CenterSugar LandTexas77478-
Utah Eye CentersBountifulUtah84010-

Find similar trials in Dothan, AL

Related Studies